Sequential lifestyle change in patients with metabolic syndrome. Edothelial impact

Investigacion Cardiovascular

Volumn 7, Issue 2, 2004, Pages 131-172

  Sabán Ruiz, José ^a   Fabregate Fuente, Rosa ^b   Fabregate Fuente, Martín ^b   Márquez Nieto, Judith ^b   Bernal, E ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b NONE

Author keywords

Diabetes; Endothelium; Exercise; Metabolic syndrome; Tobacco; Weigh

Indexed keywords

CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; AGED; ANALYTICAL ERROR; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; ENDOTHELIUM; EXERCISE; FEMALE; FOLLOW UP; FRIEDMAN TEST; HEART HEMODYNAMICS; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PULSE PRESSURE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SITTING; SMOKING CESSATION; STUDENT T TEST; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 22244478314     PISSN: 11392096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. REAVEN G M. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595-1600.
2. KAPLAN N M. The deadly quarter. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-20.
3. GARRETT B N, RASKIN P, KAPLAN N M. Metoprolol in diabetes mellitus: effect on glucose homeostasis. Clin Sci (Lond). 1980 Dec; 59 Suppl 6: 469s-472s.
4. OLEFSKY J M, CIARALDIT P, KOLTERMAN O G. Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. Am J Med. 1985 Sep 20; 79 (3B): 12-22
5. SABÁN RUIZ J. Bases Fisiopatológicas del Síndrome X. Estrategias para su prevención. Colección Hales CD 10. Editorial Doyma. Barcelona 2001.
6. STERN M P. Diabetes and cardiovascular disease. The «common soil» hypothesis. Diabetes. 1995 Apr; 44 (4): 369-74. Review.
7. MERO N, SYVANNE M, TASKINEN M R. Postprandial lipid metabolism in diabetes. Atherosclerosis. 1998 Dec; 141 Suppl 1: S53-5.
8. ANDREW R, GALE C R, WALKER B R, SECKL J R, MARTYN C N. Glucocorticoid metabolism and the Metabolic Syndrome: associations in an elderly cohort. Exp Clin Endocrinol Diabetes. 2002 Sep; 110 (6): 284-90.
9. LEBOVITZ H E, BANERJI M A. Treatment of insulin resistance in diabetes mellitus Eur J Pharmacol. 2004 Apr 19; 490 (1-3): 135-46.
10. REAVEN P. Metabolic syndrome. J. Insur Med. 2004; 36 (2): 132-42.
11. BJORNTORP P, ROSMOND R. The metabolic syndrome-a neuroendocrine disorder? Sr J Nutr 2000; 83 Suppl 1: S49-57.
12. SABAN-RUIZ J., BERNAL E., SANCHEZ-LARGO E., BAJO A., MARIN I., HAURIE J., FABREGATE R. The activation of systemic angiotensin converting enzyme as a new mechanism of hypertension in insulin resistance, correlation with intima-media thickness. 18 Scientific Meeting of the American Society 2003. New York. 14-18 Mayo 2003. (P 529, AJH-May 2003-Vol. 16, NO.5, PART 2).
13. BRAGULAT E, DE LA SIERRA A. Salt intake, endothelial dysfunction, and salt-sensitive hypertension J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4 (1): 41-6.
14. UGALDE A., CALBACHO M., BERNAL E., BAJO A., FABREGATE R., SANCHEZ-LARGO E., COCA D., SABAN-RUIZ J. The «Endothelial Battle». A New Version of «The Lord of the Rings». The Star Role of Oxidized-LDL, as Saruman, and HDL, as Gandalf. 4Th Anunual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. 8-10 Mayo 2003. Washington DC. (P389, pag.101).
15. BAJO A I, SABÁN J. Impacto de los nuevos factores de riesgo sobre la macroangiopatías diabética: homocisteína y lipoproteína a. En: Diabetes tipo 2, síndrome X y patología cardiovascular. J. Sabán Ruiz Editor. Editorial: PBM. Madrid 2002 pág 31-38.
16. SUTTON-TYRRELL K, BOSTOM A, SELHUB J, ZEIGLER-JOHNSON C. High homocysteine levels are independently related to isolated systolic hypertension in older adults Circulation. 1997 Sep 16; 96 (6): 1745-9.
17. ROLLAND P H, FRIGGI A, BARLATIER A, PIQUET P, LATRILLE V, FAYE M M, GUILLOU J, CHARPIOT P, BODARD H, GHIRINGHELLI O, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation. 1995 Feb 15; 91 (4): 1161-74.
18. HOOGEVEEN E K, KOSTENSE P J, EYSINK P E, POLAK B C, BEKS P J, JAKOBS C, DEKKER J M, NIJPELS G, HEINE R J, BOUTER L M, STEHOUWER C D. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med. 2000 Oct 23; 160 (19): 2984-90.
19. GODSLAND I F, CROOK D, PROUDLER A J, STEVENSON J C. Hemostatic Risk Factors and Insulin Sensitivity, Regional Body Fat Distribution, and the Metabolic Syndrome J Clin Endocrinol Metab. 2005 Jan; 90 (1): 190-197. Epub 2004 Oct 19.
20. BLAHA M, KREJSEK J, BLAHA V, ANDRYS J, VOKURKOVA D, MALY J, BLAZEK M, SKOREPOVA M. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol Res. 2004; 53 (3): 273-8.
21. CHARO I F, TAUBMAN M B. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004 Oct 29; 95 (9): 858-66.
22. PAN X, LI G, HU Y, WANG J, YANG W, AN Z. The Da Quing Study: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997; 20: 537-44.
23. SHIFFMAN S, WEST R, GILBERT D. SRNT Work Group on the Assessment of Craving and Withdrawal in Clinical Trials. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res. 2004 Aug; 6 (4): 599-614. Review.
24. MARTÍN LÁZARO J, SABÁN RUIZ J. Importancia de los factores de riesgo clásicos no incluídos en el Síndrome X: tabaco y LDL colesterol. En Diabetes tipo 2, síndrome X y patología cardiovascular J. Sabán Ruiz Editor. Editorial: PBM. Madrid 2002. pág: 25-30.
25. FEDDER D O, KORO C E. L'Italien GJNew National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation. 2002 Jan 15; 105 (2): 152-6.
26. WHITWORTH J A. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension J Hypertens. 2003 Nov; 21 (11): 1983-92.
27. SABÁN RUIZ J. Conceptos de diabetes mellitus, clasificación, etiopatogenia, diagnóstico, complicaciones. En Diabetes tipo 2, síndrome X y patología cardiovascular. J. Sabán Ruiz Editor. Editorial: PBM. Madrid. 2002. pág: 7-14.
28. SABÁN RUIZ J. Síndrome X plurimetabólico: concepto, impacto sociosanitario, patogenia y diagnóstico. En Diabetes tipo2, síndrome X y patología cardiovascular. J. Sabán Ruiz Editor. Editorial: PBM. Madrid. 2002. pág: 15-24.
29. SABÁN RUIZ J., COCA ROBINOT D. Bases del tratamiento antidiabético: monoterapia y terapia combinada. En Diabetes tipo2, síndrome X y patología cardiovascular. J. Sabán Ruiz Editor. Editorial: PBM. Madrid. 2002. pág: 69-76.
30. US Public Health Service Report. A Clinical Practice Guideline for Treating Tobacco Use and Dependence. JAMA 2000; 283: 3244-3254
31. HEATHERTON T F, KOZLOWSKI L T, FRECKER R C, et al. The Fagerstrom Test of Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction 1991; 86: 1119-1127
32. UUSITUPA M, LOUHERANTA A, LINDSTROM J, VALLE T, SUNDVALL J, ERIKSSON J, TUOMILEHTO J. The Finnish Diabetes Prevention Study. Br J Nutr. 2000 Mar;83 Suppl 1:S137-42.
33. TOOBERT D J, GLASGOW R E, STRYCKER L A, BARRERA M JR, RADCLIFFE J L, WANDER R C, BAGDADE J D. Biologic and quality-of-life outcomes from the Mediterranean Lifestyle Program: a randomized clinical trial. Diabetes Care. 2003 Aug; 26 (8): 2288-93
34. RISSANEN P, VAHTERA E, KRUSIUS T, UUSITUPA M, RISSANEN A. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord. 2001 Feb; 25 (2): 212-8.
35. PATE R R, PRATT M, BLAIR S N, HASKELL W L, MACERA C A, BOUCHARD C, BUCHNER D, ETTINGER W, HEATH GW, KING A C, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995 Feb 1; 273 (5): 402-7
36. O'BREIEN E, DE GAUDEMARIS R, BOBRIE G, AGABITI ROSEI E, VAISSE B. Procedings from the First International Consensus Conference on Self-Blood Pressure Measurement. Devices and Validation.-Blood Pressure Monitoring 2000; 5: 93-100.
37. TUOMILEHTO, J., LINDSTRÖN, J., ERIKSSON, J. G., et al for the Finnish Diabetes Prevention Study Group: prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 334: 1343-50.
38. Diabetes Prevention Program Research Group. Diabetes Prevention in the incidence of type 2 diabetes with lifestyle intervention or metformine. N Engl J Med 2002; 345: 393-403.
39. TORGERSON J S, et al. XENDOS: a randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27 (1): 155-161.
40. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12; 352 (9131): 837-53
41. GAEDE P H, JEPSEN P V, LARSEN J N, JENSEN G V, PARVING H H, PEDERSEN O B. The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes Ugeskr Laeger. 2003 Jun 23; 165 (26): 2658-61
42. SHICHIRI M, KISHIKAWA H, OHKUBO Y, WAKE N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients Diabetes Care. 2000 Apr; 23 Suppl 2: B21-9.
43. KASTARINEN M J, PUSKA P M, KORHONEN M H, MUSTONEN J N, SALOMAA V V, SUNDVALL J E, TUOMILEHTO J O, UUSITUPA M I, NISSINEN A M; LIHEF Study Group. Non-pharmacological treatment of hypertension in primary health care: a 2-year open randomized controlled trial of lifestyle intervention against hypertension in eastern Finland. J Hypertens. 2002 Dec; 20 (12): 2505-12.
44. RYAN D H, ESPELAND M A, FOSTER G D, HAFFNER S M, HUBBARD V S, JOHNSON K C, KAHN S E, KNOWLER W C, YANOVSKI S Z. Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003 Oct; 24 (5): 610-28.
45. Diabetes Action Now. www.who.int.
46. HAMDY O, LEDBURY S, MULLOOLY C, JAREMA C, PORTER S, OVALLE K, MOUSSA A, CASELLI A, CABALLERO A E, ECONOMIDES P A, VEVES A, HORTON E S. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome Diabetes Care. 2003 Jul; 26 (7): 2119-25.
47. CLARKSON P, MONTGOMERY HE, MULLEN MJ, DONALD AE, POWE A J, BULL T, JUBB M, WORLD M, DEANFIELD J E. Exercise training enhances endothelial function in young men. J Am Coll Cardiol. 1999 Apr; 33 (5): 1379-85.
48. Celermajer D S. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol. 1997 Aug; 30 (2): 325-33